Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTXNASDAQ:GMTXNASDAQ:MIRMNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$22.34+0.4%$26.40$14.90▼$38.12$2.09B0.22942,558 shs254 shsGMTXGemini Therapeutics$52.79-1.7%$55.06$1.16▼$14.10$2.29B-0.12189,291 shs182,245 shsMIRMMirum Pharmaceuticals$46.64+0.8%$48.02$23.14▼$54.23$2.29B1.04510,718 shs317,128 shsPHARPharming Group$8.86+0.9%$8.85$6.65▼$11.30$602.76M-0.16,168 shs304 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics-2.37%-9.48%-11.00%-24.95%+29.87%GMTXGemini Therapeutics-1.69%-0.08%-3.19%-18.80%-12.45%MIRMMirum Pharmaceuticals-1.66%-1.80%-9.17%+10.11%+85.71%PHARPharming Group-0.11%-2.52%-5.07%-17.88%-19.62%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWTXEdgewise Therapeutics1.7948 of 5 stars3.41.00.00.02.22.50.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals4.3919 of 5 stars3.52.00.04.23.33.30.6PHARPharming Group2.1326 of 5 stars3.53.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.88Moderate Buy$45.38103.12% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 3.09Buy$58.2024.79% UpsidePHARPharming Group 3.00Buy$30.00238.60% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, MIRM, GMTX, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/4/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $56.002/28/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.002/27/2025MIRMMirum PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $55.001/22/2025EWTXEdgewise TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$30.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMIRMMirum Pharmaceuticals$336.89M6.79N/AN/A$5.33 per share8.75PHARPharming Group$297.20M2.03$0.10 per share91.82$3.26 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMIRMMirum Pharmaceuticals-$163.41M-$1.85N/AN/AN/A-31.69%-41.22%-14.81%5/6/2025 (Estimated)PHARPharming Group-$10.55M-$0.17N/A295.33N/A-6.09%-7.65%-3.82%5/6/2025 (Estimated)Latest PHAR, MIRM, GMTX, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 million3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A26.3526.35GMTXGemini TherapeuticsN/A71.4971.49MIRMMirum Pharmaceuticals1.333.343.15PHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AGMTXGemini Therapeutics75.42%MIRMMirum PharmaceuticalsN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics24.11%GMTXGemini Therapeutics12.90%MIRMMirum Pharmaceuticals22.87%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics6095.21 million71.86 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMIRMMirum Pharmaceuticals14049.01 million37.03 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionablePHAR, MIRM, GMTX, and EWTX HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Trading Down 2% - Here's WhyMarch 25 at 12:26 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's WhyMarch 22, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Earns "Buy" Rating from HC WainwrightMarch 22, 2025 | americanbankingnews.comPharming doses first patient in phase II trial of leniolisib for common variable immunodeficiency with immune dysregulationMarch 22, 2025 | pharmabiz.comHC Wainwright Reiterates "Buy" Rating for Pharming Group (NASDAQ:PHAR)March 21, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's WhyMarch 20, 2025 | marketbeat.comPharming Group Begins Phase II Trial for CVID TreatmentMarch 20, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Trading Down 3.6% - What's Next?March 18, 2025 | marketbeat.comPharming Group's (PHAR) Buy Rating Reiterated at HC WainwrightMarch 17, 2025 | americanbankingnews.comWhat Analysts Are Saying About Pharming StockMarch 17, 2025 | benzinga.comPharming Group (NASDAQ:PHAR) Price Target Raised to $39.00 at OppenheimerMarch 15, 2025 | marketbeat.comPharming Group's (PHAR) Buy Rating Reaffirmed at HC WainwrightMarch 15, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's WhyMarch 14, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Releases Earnings Results, Misses Estimates By $0.02 EPSMarch 14, 2025 | marketbeat.com3 European Penny Stocks With Market Caps Over €300MMarch 14, 2025 | uk.finance.yahoo.comPharming Group (NASDAQ:PHAR) Short Interest UpdateMarch 14, 2025 | marketbeat.comPharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...March 14, 2025 | gurufocus.comPharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growthMarch 14, 2025 | msn.comPharming Group Full Year 2024 Earnings: EPS Beats ExpectationsMarch 14, 2025 | uk.finance.yahoo.comQ4 2024 Pharming Group NV Earnings Call TranscriptMarch 14, 2025 | gurufocus.comPharming Group Reports Strong Revenue Growth for 2024March 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Stocks With Ironclad Balance Sheets for Long-Term StabilityBy Leo Miller | March 13, 2025View 3 Stocks With Ironclad Balance Sheets for Long-Term StabilityEli Lilly Pours $27B Into U.S. Growth—What It Means for InvestorsBy Leo Miller | March 6, 2025View Eli Lilly Pours $27B Into U.S. Growth—What It Means for InvestorsPharma Frenzy: Volatility Ignites Biotech SectorBy Jeffrey Neal Johnson | March 25, 2025View Pharma Frenzy: Volatility Ignites Biotech SectorHidden Gems: 5 Stocks Under $10 With Massive Growth PotentialBy Jeffrey Neal Johnson | March 11, 2025View Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential4 Sectors That Thrive When Inflation Runs HotBy Chris Markoch | February 28, 2025View 4 Sectors That Thrive When Inflation Runs HotPHAR, MIRM, GMTX, and EWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$22.34 +0.08 (+0.35%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Gemini Therapeutics NASDAQ:GMTX$52.79 -0.91 (-1.69%) As of 03/25/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$46.64 +0.36 (+0.78%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Pharming Group NASDAQ:PHAR$8.86 +0.08 (+0.91%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Energy Transfer: Powering Data With Dividends and Diversification Advanced Micro Devices Can Double in Price: Here’s Why Palantir Setting Up to Be a Big Winner With New Defense Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
